Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Recursion Pharmaceuticals focuses on innovative drug discovery with a streamlined R&D pipeline in oncology and rare diseases.

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

WARNING: THIS PROJECT IS NO LONGER MAINTAINED. Python/NumPy implementation of the Ramer-Douglas-Peucker algorithm (Ramer 1972; Douglas and Peucker 1973) for 2D and 3D data. The Ramer-Douglas-Peucker ...